Drug profile · INN
marstacimab
HYMPAVZI
marstacimab (HYMPAVZI) is a tissue factor pathway inhibitor inhibitor.
EMA: approved PMDA: approved Blood and blood forming organs (B02) B02BX11
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — marstacimab
- Class
- Blood and blood forming organs (B02)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
marstacimab (HYMPAVZI) is a tissue factor pathway inhibitor inhibitor.
Key facts
INN marstacimab
Brand HYMPAVZI
Mechanism Tissue factor pathway inhibitor inhibitor
Target Tissue factor pathway inhibitor
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BX11
Mechanism of action
Tissue factor pathway inhibitor inhibitor
Primary target: Tissue factor pathway inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is marstacimab?
marstacimab (HYMPAVZI) is a tissue factor pathway inhibitor inhibitor.
What is the brand name for marstacimab?
HYMPAVZI is a marketed brand name for marstacimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.